Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 790 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... September 10, 2022 Best Friends and Owners of a Specialty Cheese Shop Battle Breast... June 11, 2021 Ενθαρρυντικά δεδομένα για ασθενείς με προχωρημένο μελάνωμα που έλαβαν θεραπεία με... June 24, 2019 Associations Between Genomic Features and Response to Neoadjuvant Treatment in a... August 30, 2022 Load more HOT NEWS Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... Looking back at a life-changing clinical trial Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya... Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer
